Related Experiment Videos

Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?

Jasper J Brugts1, Maarten L Simoons

  • 1Department of Cardiology, Erasmus University Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. j.brugts@erasmusmc.nl

Expert Review of Cardiovascular Therapy
|October 4, 2012
PubMed

Insights

Pharmacogenetics offers personalized medicine by studying genetic factors influencing angiotensin-converting enzyme (ACE) inhibitor effectiveness in stable coronary artery disease patients. Recent studies suggest this approach is becoming feasible for tailored hypertension and heart failure treatments.

Area of Science:

  • Pharmacology
  • Genetics
  • Cardiology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are crucial for hypertension, coronary artery disease, and heart failure.
  • Personalizing ACE inhibitor therapy based on clinical risk factors is challenging in low-risk patients.
  • Pharmacogenetics presents a potential avenue for personalized medicine by considering individual patient genetic factors.

Purpose of the Study:

  • To review recent advancements in pharmacogenetic research concerning ACE inhibitors.
  • To explore the feasibility of pharmacogenetics in tailoring ACE inhibitor treatment for stable coronary artery disease.
  • To identify genetic targets within the renin-angiotensin-aldosterone system for pharmacogenetic studies.

Main Methods:

  • Review of recent pharmacogenetic studies on ACE inhibitors.
  • Analysis of genetic targets within the renin-angiotensin-aldosterone system.
  • Focus on patients with stable coronary artery disease.

Main Results:

  • Previous pharmacogenetic studies yielded scarce and inconsistent results.
  • Recent larger-scale studies indicate the feasibility of a pharmacogenetic approach.
  • The renin-angiotensin-aldosterone system is a plausible target for pharmacogenetic investigations.

Conclusions:

  • Pharmacogenetics holds promise for personalized medicine in ACE inhibitor therapy.
  • Recent research supports the future feasibility of pharmacogenetic approaches.
  • Tailoring ACE inhibitor treatment based on genetic profiles may improve outcomes in stable coronary artery disease.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...